Previous Close | 0.5800 |
Open | 0.6100 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.5900 - 0.6130 |
52 Week Range | 0.4500 - 9.6000 |
Volume | |
Avg. Volume | 123,345 |
Market Cap | 14.274M |
Beta (5Y Monthly) | 1.91 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -9.7900 |
Earnings Date | Apr 01, 2024 - Apr 05, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for VBIV
By Daniella Parra Brii Biosciences and VBI Vaccines (NASDAQ: VBIV) said they will expand and control of BRII-179 supplies, a late-stage asset for HBV functional cure. Initially, a $2.5 million promissory note will be issued, eliminating royalty and milestone payments for PreHevbri and upon meeting conditions, the note will increase to $10 million, securing VBI’s […]
CAMBRIDGE, Mass., February 14, 2024--VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced agreements whereby Brii Biosciences ("Brii Bio"), subject to certain activities, is expected to: (i) acquire the intellectual property for VBI-2601, VBI’s HBV immunotherapeutic development program, and eliminate payment obligations from the July 2023 agreements between VBI a
CAMBRIDGE, Mass., November 20, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients, were highlighted in a poster presentation at the 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SN